# Objective Evaluation of Ocular Surface Adverse Effects in Patients Receiving Topical Antiglaucoma Treatment

## TL;DR

This study evaluates how different glaucoma eye drops affect the health of the eye's surface in patients.

## Contribution

The study highlights the influence of the number of daily eye drops on ocular surface health, beyond preservative effects.

## Key findings

- The number of daily eye drops may more strongly affect ocular surface health than preservatives.
- Ocular surface health was assessed using Schirmer test, TBUT, and fluorescein staining.
- The study monitored patients from February 2019 to September 2024.

## Abstract

Topical treatments remain the primary therapeutic strategy for glaucoma, with the primary objective of reducing intraocular pressure (IOP), the only modifiable risk factor for the disease. While these medications are effective in lowering IOP, they are also associated with a variety of potential adverse effects.

This study aims to compare the effects of various topical antiglaucoma medications on the ocular surface in patients with open-angle glaucoma or intraocular hypertension. Patients were classified based on their treatment type and assessed using the Schirmer test, tear break-up time (TBUT), and fluorescein staining. The monitoring period spanned from February 2019 to September 2024.

Preliminary results suggested that the daily number of drops administered may have a more significant impact on outcomes than the presence or absence of preservatives in the eye drops.